Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a ...

Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...

William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...

William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zoetis (ZTS – Research Report), Terns ...

Pre-Market: 5:08:48 a.m. EST Loading Chart for MRSN ...

Copa (NYSE:CPA – Get Free Report) is anticipated to release its earnings data after the market closes on Wednesday, February 12th. Analysts expect the company to announce earnings of $3.87 per share ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

JP Morgan analyst Samik Chatterjee initiated coverage on Jamf Holding Corp. JAMF with an Overweight rating and announced a ...

After hours: February 3 at 4:09:01 PM EST Loading Chart for SPRO ...

After hours: 7:31:34 p.m. EST ...